Syn-Coll

Syn-Coll is the trade name for palmitoyl tripeptide-5, a synthetic lipopeptide with the sequence palmitoyl-Lys-Val-Lys (CAS 623172-55-4; molecular weight approximately 611.9 g/mol as free base). It was developed by Pentapharm, now part of DSM-Firmenich, and functions as a growth factor activator rather than a conventional matrikine or carrier peptide.

The central mechanism relies on molecular mimicry of thrombospondin-1 (TSP-1), a naturally occurring extracellular matrix glycoprotein. TSP-1 activates latent transforming growth factor-beta (TGF-beta) by inducing a conformational change that releases the active cytokine from its latent complex in the extracellular matrix. The Lys-Val-Lys tripeptide replicates a functional motif within TSP-1 that initiates this activation, engaging TGF-beta receptor complexes on dermal fibroblasts and stimulating SMAD-dependent downstream signaling.

Downstream effects reported in preclinical models include upregulation of type I and type III collagen mRNA and protein, fibronectin, and hyaluronic acid synthesis in normal dermal fibroblasts. Separately, in vitro data indicate the peptide inhibits matrix metalloproteinases MMP-1 and MMP-3, enzymes that degrade collagen fibrils and other extracellular matrix components, providing a dual mechanism of promoting collagen synthesis while slowing its degradation.

• The palmitoyl (C16 fatty acid) conjugation increases the peptide's lipophilicity, enhancing permeation across the stratum corneum relative to the unmodified tripeptide. • Formulation pH should be maintained between 5.0 and 7.0 and processing temperature kept below 40 degrees C to preserve peptide integrity.

All identified clinical evidence for Syn-Coll originates from manufacturer-sponsored studies conducted by Pentapharm/DSM. No independent randomized controlled trials, systematic reviews, or peer-reviewed journal publications specifically evaluating palmitoyl tripeptide-5 as a standalone ingredient were identified. This absence of independent replication is a significant limitation when interpreting the available outcome data.

In the most-cited Pentapharm/DSM study, 45 volunteers applied creams containing either 1% or 2.5% Syn-Coll twice daily for 84 days. PRIMOS surface topography was used to quantify wrinkle parameters. At 1% concentration, wrinkle appearance was reduced by approximately 7%; at 2.5%, the reduction was approximately 12%. The higher concentration formulation reportedly achieved approximately 3.5 times greater wrinkle reduction than a matching placebo in this same study.

A separate manufacturer study enrolling 33 female volunteers over 4 weeks found that 77% of participants self-reported visible improvement in skin firmness and elasticity, and 60% reported a reduction in pore size appearance. These outcomes relied on self-assessment questionnaires rather than objective instrumented measurement.

Manufacturer technical literature also claims that Syn-Coll stimulated type I collagen production approximately 60% more effectively than palmitoyl pentapeptide-3 (Matrixyl) in a fibroblast cell culture comparison, and references data showing no irritation over a 12-week photodamage study with measurable reductions in global photodamage scores. Specific publication details for these comparisons were not available in the sources reviewed.

A comparative marketing claim citing up to 35% wrinkle depth reduction and 25% skin firmness improvement with a 4% formulation after 84 days appears in DSM product literature but could not be traced to a published peer-reviewed source.

Given the consistent manufacturer sponsorship and the absence of independent replication, all quantitative outcomes should be regarded as preliminary and potentially subject to reporting bias.

Typical dosage: Topical formulation (daily).

Syn-Coll is formulated and sold exclusively for topical cosmetic application. It is not intended or approved for injectable, oral, or systemic use.

In finished cosmetic formulations, the active peptide is typically incorporated at a concentration of 1% to 3% by weight. DSM-Firmenich supplies the ingredient commercially as SYN-COLL, an aqueous concentrate containing palmitoyl tripeptide-5 dissolved in water and glycerin. Formulators add this concentrate at 2% to 5% by weight to the finished product, which delivers an effective peptide concentration in the range evaluated in manufacturer clinical studies.

The 84-day manufacturer study used twice-daily application (morning and evening) at 1% and 2.5% concentrations. Most manufacturer guidance recommends consistent twice-daily use for a minimum of 8 to 12 weeks to observe measurable change. The 4-week self-assessment study at 33 subjects suggests some perceptible subjective change may occur sooner, but objective topographic improvement in the 84-day study was modest at 7 to 12% across concentration levels.

Formulation stability requirements specify pH 5.0 to 7.0 and a maximum processing temperature of 40 degrees C (104 degrees F). Combining with strongly acidic actives (pH below 3.5) may reduce peptide stability and is generally avoided.

This information is provided for educational and reference purposes only and does not constitute medical advice. Individuals seeking cosmetic or medical treatment should consult a qualified licensed healthcare professional before use.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In cosmetic formulation practice, Syn-Coll is most frequently combined with hyaluronic acid, on the rationale that hyaluronic acid augments superficial hydration while Syn-Coll targets deeper dermal collagen architecture. Niacinamide is another common co-ingredient, valued for barrier repair and pigmentation support, and is chemically compatible with palmitoyl peptides across typical formulation pH ranges.

Stable vitamin C derivatives such as tetrahexyldecyl ascorbate are also paired with Syn-Coll to provide antioxidant protection against oxidative degradation of newly synthesized collagen.

Among peptide combinations, formulators and consumers anecdotally report stacking Syn-Coll with palmitoyl pentapeptide-4 (Matrixyl), acetyl hexapeptide-3 (Argireline), and copper peptide GHK-Cu, reasoning that these compounds engage distinct receptor mechanisms and may produce additive or complementary effects on the extracellular matrix. This multi-peptide rationale remains anecdotal; no published clinical trials comparing single- versus multi-peptide formulations containing Syn-Coll were identified in this review.

Retinoids are sometimes used in alternating regimens with peptide serums. Direct co-formulation with high concentrations of L-ascorbic acid (pH below 3.5) or strong alpha-hydroxy acid peels is generally avoided due to potential peptide bond hydrolysis under highly acidic conditions.

Syn-Coll is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Topically safe

Palmitoyl tripeptide-5 demonstrates a favorable safety profile in the context of topical cosmetic application. Manufacturer clinical studies at concentrations up to 2.5% reported no significant irritation, erythema, or sensitization events across test populations. Consumer-facing dermatology sources and ingredient safety databases classify the ingredient as low-hazard for routine cosmetic use.

The Cosmetic Ingredient Review (CIR) Expert Panel has conducted a safety assessment of palmitoyl oligopeptides as a class. The CIR concluded this class of ingredients is safe for use in cosmetic formulations, subject to standard concentration limits appropriate to cosmetic use.

A theoretical safety consideration involves TGF-beta overactivation. In systemic pathology and wound-healing contexts, dysregulated TGF-beta signaling is associated with fibrosis and hypertrophic scar formation. However, topical peptide application creates a localized and transient signal at the skin surface; the peptide does not reach systemic circulation at clinically meaningful concentrations, and fibrotic adverse events have not been reported in association with cosmetic TGF-beta-activating peptides.

Occasional mild transient stinging or redness may occur on initial application in sensitive individuals, consistent with the general experience across cosmetic peptide actives. Allergic contact dermatitis to palmitoyl peptides is rare but has been reported as an isolated case in individuals with broader peptide hypersensitivity.

No clinical safety data are available for use during pregnancy or breastfeeding. No evidence of comedogenicity, hormonal disruption, or phototoxicity has been reported. Syn-Coll is classified and marketed in most jurisdictions as a cosmetic ingredient, not as a pharmaceutical drug, and it holds no drug regulatory approval for any indication.